弥漫性大B细胞淋巴瘤中期与治疗结束时18F-FDG PET/CT的观察者间一致性:对临床实践与试验的影响
基于HOVON84随机对照试验中弥漫性大B细胞淋巴瘤(DLBCL)患者的中期PET(I-PET)和治疗结束时PET(EoT-PET)扫描,由两名独立中心评审员依据Deauville评分(DS)回顾性评分并二分为阴性(DS 1-3)或阳性(DS 4-5)。I-PET与EoT-PET的总体一致率分别为87.7%和91.7%(P=0.049),阴性一致率分别为92.0%和95.0%(P=0.091),阳性一致率分别为73.7%和76.3%(P=0.656)。结论认为总体一致率和阴性一致率较高,但阳性一致率较低,提示EoT-PET/CT日常治疗评估或可从双读片获益,I-PET适应性试验或可从中心评审获益。
要点
- I-PET与EoT-PET的总体一致率分别为87.7%和91.7%(P=0.049)。
- 阴性一致率分别为92.0%和95.0%(P=0.091),阳性一致率分别为73.7%和76.3%(P=0.656)。
- 阳性一致率较低,作者认为EoT-PET/CT日常评估或可受益于双读片,I-PET适应性试验或可受益于中心评审。
核心结论
- 使用DS在DLBCL患者I-PET和EoT-PET中观察者间一致性的总体一致率和阴性一致率较高,但阳性一致率较低,作者认为EoT-PET/CT日常治疗评估或可从双读片获益,I-PET适应性试验或可从中心评审获益。
研究设计与样本
- 基于HOVON84研究(2007-2012年)的国际多中心随机对照试验,患者接受R-CHOP14方案并随机分配是否在前4个周期接受利妥昔单抗强化治疗。
- I-PET在第4周期后进行(用于观察目的),EoT-PET在第6或8周期后进行。
- 两名独立中心评审员对全部扫描按DS系统回顾性评分,对临床结局设盲,结果二分为阴性(DS 1-3)或阳性(DS 4-5)。
- 共中心评审465例I-PET和457例EoT-PET扫描;基线18F-FDG PET或PET/CT在75%-77%的病例中可用,其余病例有CT可用。
主要发现
- I-PET与EoT-PET的总体一致率分别为87.7%和91.7%(P=0.049)。
- I-PET与EoT-PET的阴性一致率分别为92.0%和95.0%(P=0.091)。
- I-PET与EoT-PET的阳性一致率分别为73.7%和76.3%(P=0.656)。
临床怎么用
- 作者认为EoT-PET/CT日常治疗评估或可从双读片获益,I-PET适应性试验或可从中心评审获益。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We aimed to assess the interobserver agreement of interim PET (I-PET) and end-of-treatment PET (EoT-PET) using the Deauville score (DS) in first-line diffuse large B-cell lymphoma (DLBCL) patients. Methods: I-PET and EoT-PET scans of DLBCL patients were performed in the HOVON84 study (2007-2012), an international multicenter randomized controlled trial. Patients received R-CHOP14 and were randomized to receive rituximab intensification in the first 4 cycles or not. I-PET was performed after 4 cycles (for observational purposes), and EoT-PET after 6 or 8 cycles. Two independent central reviewers retrospectively scored all scans according to the DS system, masked to clinical outcomes. Results were dichotomized as negative (DS of 1-3) or positive (DS of 4-5). Besides percentage overall agreement (OA), we calculated agreement for positive and negative scores, expressed as positive agreement (PA) and negative agreement (NA), respectively. Results: 465 I-PET and 457 EoT-PET scans were centrally reviewed; baseline 18F-FDG PET or PET/CT was available in 75%-77%, and CT in the remaining cases. Percentage OA for I-PET and EoT-PET were 87.7% and 91.7% (P = 0.049), with NA of 92.0% and 95.0% (P = 0.091), and PA of 73.7% and 76.3% (P = 0.656), respectively. Conclusion: Interobserver agreement using DS in DLBCL patients in I-PET and EoT-PET yields high OA and NA. The lower PA suggests that EoT-PET/CT treatment evaluation in daily practice and I-PET-adapted trials may benefit from dual reads and central review, respectively.
引用
- Burggraaff CN, Cornelisse AC, Hoekstra OS, et al. Interobserver Agreement of Interim and End-of-Treatment 18F-FDG PET/CT in Diffuse Large B-Cell Lymphoma: Impact on Clinical Practice and Trials. J Nucl Med. 2018. PMID: 29728515. doi:10.2967/jnumed.118.210807
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。